Pirfenidone Tablet, Film Coated
Product Images NDC 0904-7397

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Pirfenidone (NDC 0904-7397). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pirfenidone-267mg-90s-container-label (Pirfenidone 267mg 90s Container Label)

Label for Pirfenidone 267 mg film-coated tablets by Major Pharmaceuticals. The label indicates the product is prescription-only and contains 90 tablets. It lists storage instructions, manufacturer (MSN Pharmaceuticals Inc.), and distributor details (Major Pharmaceuticals, Indianapolis, IN). The label also includes the NDC 0904-7397-89 and a barcode.*

FDA Label Image

Pirfenidone-267mg-carton-container-label (Pirfenidone 267mg Carton Container Label)

Packaging label for Pirfenidone Tablets, 267 mg film-coated tablets by Major Pharmaceuticals. The label states the product is prescription only, with a total of 270 tablets provided in 3 bottles of 90 tablets each. It includes storage instructions and manufacturer information for MSN Pharmaceuticals Inc., Piscataway, NJ.*

FDA Label Image

Pirfenidone-801mg-90s-container-label (Pirfenidone 801mg 90s Container Label)

Label for Pirfenidone 801 mg film-coated tablets by Major Pharmaceuticals. The label shows the product name, strength (801 mg), and quantity (90 tablets). It includes storage instructions, manufacturing and distribution information, and is marked Rx Only. The label includes barcodes, NDC 0904-7398-89, and revision date 10/23.*

FDA Label Image

Fig1 (Pirfenidone Figure 1)

A cumulative distribution plot showing the percentage of patients by absolute change in %FVC (Forced Vital Capacity) from baseline to week 52. The plot compares Pirfenidone (n=278, solid line) and placebo (n=277, dotted line) groups, indicating worsening (decrease in %FVC) versus no decline (increase in %FVC). Key percentage values are marked along the lines for both groups.*

FDA Label Image

Fig2 (Pirfenidone Figure 2)

A line graph depicting mean change in forced vital capacity (FVC) in mL over a 52-week period for two groups: one treated with Pirfenidone (solid line) and one with placebo (dashed line). The Pirfenidone group shows a smaller decline in FVC compared to placebo across weeks 0, 13, 26, 39, and 52.*

FDA Label Image

Fig3 (Pirfenidone Figure 3)

A survival curve chart comparing the percentage of patients alive over time in weeks for Pirfenidone versus placebo groups. The solid line represents Pirfenidone (n=623) and the dashed line represents placebo (n=624). The graph includes patient counts at risk at various time points and a hazard ratio with confidence interval, illustrating survival trends over approximately 120 weeks.*

FDA Label Image

Str (Pirfenidone Str)

Chemical structure of pirfenidone showing a pyridone ring with a methyl group and a phenyl ring attached through a nitrogen atom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.